<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AD4088FA-6FCC-4FDB-ABBC-0CE9592F0B75"><gtr:id>AD4088FA-6FCC-4FDB-ABBC-0CE9592F0B75</gtr:id><gtr:name>Centre for Life</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DF79FD97-AFC0-4E12-B081-3BF8E8ABCB2C"><gtr:id>DF79FD97-AFC0-4E12-B081-3BF8E8ABCB2C</gtr:id><gtr:name>Wellcome Trust Case Control Consortium 2 (WTCCC)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AD4088FA-6FCC-4FDB-ABBC-0CE9592F0B75"><gtr:id>AD4088FA-6FCC-4FDB-ABBC-0CE9592F0B75</gtr:id><gtr:name>Centre for Life</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DF79FD97-AFC0-4E12-B081-3BF8E8ABCB2C"><gtr:id>DF79FD97-AFC0-4E12-B081-3BF8E8ABCB2C</gtr:id><gtr:name>Wellcome Trust Case Control Consortium 2 (WTCCC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7BB1FCBA-BC86-4DE3-9404-E41BB4849178"><gtr:id>7BB1FCBA-BC86-4DE3-9404-E41BB4849178</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Beeson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701521"><gtr:id>4D660888-F87D-49F3-A612-4121D390E3F7</gtr:id><gtr:title>Genes, mechanisms, models and treatments for hereditary myasthenia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701521</gtr:grantReference><gtr:abstractText>Signalling between nerves is achieved largely by the opening and closing of ion channels, in their cell surface, at specialised sites called synapses. We believe an understanding of how synapses malfunction will help in finding the causes of many neurological disorders and in devising new therapies. We study inherited diseases, called congenital myasthenic syndromes, that cause severe disability in children and adults and affect ion channels, called acetylcholine receptors (AChR), located at the connection between nerves and muscles. These inherited mutations cause disease by affecting AChR in different ways. Understanding how the mutations cause disease enables us to give patients correct treatments and genetic counselling, and provides the knowledge base required for exploring new therapies. Several different genes have been shown to cause these disorders but in around 40% of cases the underlying defect is not known. Recently we identified mutations in a new gene, called DOK7. Standard treatments used in congenital myasthenia often make patients with DOK7 mutations worse. It is thought the faulty gene underlies a defect in the process that places the receptor in the correct position opposite the nerve ends. Here, in studies of this process we will learn why the signal from the nerve is not received by the muscle. Knowledge gained will help identify new genes involved in our disease, and help us understand why these patients do not respond to standard treatments. At present many patients with these mutations go undiagnosed or are misdiagnosed. Success in this project should prevent misdiagnosis, and enable us to provide better treatment for our patients.</gtr:abstractText><gtr:technicalSummary>Congenital myasthenic syndromes (CMS) stem from genetic defects that affect transmission of information from nerves to muscles at the neuromuscular junction (NMJ) and result in fatiguable muscle weakness. They comprise a disabling and sometimes potentially lethal set of disorders with subtly different clinical features that arise from different underlying molecular mechanisms. Understanding the different disease mechanisms enables appropriate treatments to be given to patients, facilitates investigations of more common CNS disorders, and provides prototypic examples of synaptic dysfunction that may be used to evaluate new treatment strategies. 
Acetylcholine receptors (AChR) are the ion channels that receive the signal for muscle contraction. Many mutations in CMS patients are in the AChR, but it is now apparent that an equal number will be identified in proteins that are responsible for the localisation and clustering of the AChR and also in maintaining the synaptic structure. We have detected a large number of mutations both in the AChR-clustering protein rapsyn and the newly identified muscle protein, Dok-7. Dok-7 has been identified as an essential component of the AChR clustering pathway. 

The objective of this proposal is threefold: i) to investigate the molecular mechanisms of pathogenic mutations that impair AChR clustering, ii) to identify novel CMS-associated genes that are expressed on the postsynaptic side of the neuromuscular junction, and iii) to study current and novel therapies for congenital myasthenic syndromes in cellular and mouse models of disease.

In studies of rapsyn and Dok-7 mutations we have developed and are acquiring an exceptional set of experimental tools, including EGFP-tagged functional AChR, a series of pathogenic mutants, ?knock out? muscle cell lines and transgenic disease models, including a model of DOK7 CMS. We shall use these in a combination of microscopic, biochemical and genetic techniques to investigate the defective signalling from MuSK to the AChR that results in reduced and less stable rapsyn-associated clustering. We will use a multifaceted approach, including linkage analysis, the study of fetal akinesis, and knowledge of the MuSK signalling pathway to identify new candidate CMS genes. Therapies for CMS will be given to our transgenic mouse disease models and their response will be analysed in vivo by electromyography and ex vivo by electrophysiology, microscopy, and biochemical analysis</gtr:technicalSummary><gtr:fund><gtr:end>2013-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1417239</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centre for Life</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>OXION collaboration</gtr:description><gtr:id>86611E2F-143E-4716-927A-AB356C7808BF</gtr:id><gtr:impact>A series of papers have been generated in which phenotypic characteristics of the different types of congenital myasthenic syndromes are described</gtr:impact><gtr:outcomeId>r8qadMqFNh1-2</gtr:outcomeId><gtr:partnerContribution>Uncovering the pathogen mechanism of DEND syndrome (juvenile hereditary diabetes). We collaborated to find out is deficit was of due to dysfunction in the CNS or at the NMJ.</gtr:partnerContribution><gtr:piContribution>Collaborate over access to patient data, genetic screening.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>GOSH collaboration on CMS</gtr:description><gtr:id>4550D530-9F9D-46F3-AA31-95B01A859075</gtr:id><gtr:impact>To date 3 papers on phenotypic features on patients with congenital myasthenic syndromes</gtr:impact><gtr:outcomeId>nrVRf3cjJvh-1</gtr:outcomeId><gtr:partnerContribution>Pooling of Patients and patient data in orderto gain further knowledge about rare muscle conditions</gtr:partnerContribution><gtr:piContribution>Enables enough data on patients to be gathered so that general patterns of genotype-phenotype correlations can be ascertained</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust Case Control Consortium 2 (WTCCC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>WGS500 consortium</gtr:description><gtr:id>C8CE5603-0B8D-4DAC-8F16-177B051F5151</gtr:id><gtr:impact>Pathogenic mutations in new genes identified

Cossins et al. (submitted)</gtr:impact><gtr:outcomeId>qA3axZbqj3M-1</gtr:outcomeId><gtr:partnerContribution>Identification of appropriate DNA samples

Functional analysis of variants to determine if they are pathogenic</gtr:partnerContribution><gtr:piContribution>Providing patient DNA and analysis of identified variants for identification rare Mendelian disorders</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Neuromuscular Diseases</gtr:department><gtr:description>MRC neuromuscular centre</gtr:description><gtr:id>86A764EA-DABD-4C15-AC58-4EAB7D2F8603</gtr:id><gtr:impact>Publications identifying a new gene in which mutations can underlie congenital myasthenic syndromes, and characterisation of the syndrome phenotype</gtr:impact><gtr:outcomeId>XdDbWLLRfNG-1</gtr:outcomeId><gtr:partnerContribution>Provision of patients and scientific data</gtr:partnerContribution><gtr:piContribution>Supplied patient data, mutation data, functional laboratory studies</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physiology, Anatomy and Genetics</gtr:department><gtr:description>OXION collaboration</gtr:description><gtr:id>EE2625F0-EFEF-4B0E-9947-CD8F781C8D6D</gtr:id><gtr:impact>A series of papers have been generated in which phenotypic characteristics of the different types of congenital myasthenic syndromes are described</gtr:impact><gtr:outcomeId>r8qadMqFNh1-1</gtr:outcomeId><gtr:partnerContribution>Uncovering the pathogen mechanism of DEND syndrome (juvenile hereditary diabetes). We collaborated to find out is deficit was of due to dysfunction in the CNS or at the NMJ.</gtr:partnerContribution><gtr:piContribution>Collaborate over access to patient data, genetic screening.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wellcome Trust Centre for Human Genetics</gtr:department><gtr:description>WGS500 consortium</gtr:description><gtr:id>201F1775-B480-4778-9EC2-5C209EED37AB</gtr:id><gtr:impact>Pathogenic mutations in new genes identified

Cossins et al. (submitted)</gtr:impact><gtr:outcomeId>qA3axZbqj3M-2</gtr:outcomeId><gtr:partnerContribution>Identification of appropriate DNA samples

Functional analysis of variants to determine if they are pathogenic</gtr:partnerContribution><gtr:piContribution>Providing patient DNA and analysis of identified variants for identification rare Mendelian disorders</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient video</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>22CF1B16-4A14-4744-B4DD-20996AE60B5B</gtr:id><gtr:impact>Video to inform patients about their condition, problems they might encounter in everyday management of their condition, such as when at school, and information on the research that is being carried out into their condition

Very positive feedback from patient groups</gtr:impact><gtr:outcomeId>mXLNszNnmpH</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Articles in the MGA news letters</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E0E2C467-1FE6-4556-A171-C70DC798D35D</gtr:id><gtr:impact>We provide updates on latest research in the field

Do not usually get feedback from this but believe the patients groups are keen to keep up with what is going on.</gtr:impact><gtr:outcomeId>RsPceSYREod</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford CMS Research Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2AC58D45-FBBA-42E9-856E-0DE3F51F819C</gtr:id><gtr:impact>Approx 250 pateints + familes attend a research open day for lectures about research, patient questions to clinicians, and visits to the laboratories.

Good patient feedback with lots of questions and it gives us an opportunity to update the patients on what we have achieved.</gtr:impact><gtr:outcomeId>Fyr72WZ4nDe</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2008,2010,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture in science week</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>95EFD2D0-AE51-4498-941A-73537D98CA6E</gtr:id><gtr:impact>Audience from the general public of around 125 people attended seminar presentation. Question and answer session after talk

Several pupils and schools asked for work experience placements</gtr:impact><gtr:outcomeId>nmW49ZUtnUz</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Congenital myasthenic syndrome open day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6308E8C3-5CDB-4B2E-BDCD-F0EA816A5CB4</gtr:id><gtr:impact>Patient day. Patients are given a series of lectures on scientific research updates, and then in the afternoon there are a series of workshops for particular patient groups where needs that have been identified or areas of special interest are addressed. Typically this might involve treatments, exercise, benefits, future therapy updates.

Patients and researchers are both enthused about the research effort</gtr:impact><gtr:outcomeId>885B5E80795</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.ouh.nhs.uk/services/referrals/neurosciences/myasthenia.aspx</gtr:url><gtr:year>2006,2008,2010,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient information pamphlet</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E7BE7E03-6B66-4109-8530-7384FC54761C</gtr:id><gtr:impact>The pamphlet is used by families to inform them about their disorder and to take to their schools to inform them about the disorder that the children have. This enables the schools to understand the childs condition and to put in place appropriate safeguards and facilities to ensure the patient is safe and to enable adaptations to allow a full potential for learning to be in place.

Should help school, social workers to understand patient disabilities and their special needs when at school.</gtr:impact><gtr:outcomeId>A7rGnj4ns5f</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.ouh.nhs.uk/services/referrals/neurosciences/myasthenia.aspx</gtr:url><gtr:year>2010,2011,2012,2013,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talks to patient group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A5E4C628-8682-46D8-B5DD-A8174836C468</gtr:id><gtr:impact>Updating patient support groups on the research activities.


Patients are always interested in their disorders and usually ask lots of questions.</gtr:impact><gtr:outcomeId>i8j9FUUHPJB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Work experience</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EBE85DC3-68E4-4413-BAB8-C58B123B8615</gtr:id><gtr:impact>Individual students spend a week in the laboratory learning about scientific research.

School comes back each year requesting further pupil experience.</gtr:impact><gtr:outcomeId>FXxCfJfBJfB</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MDC Prize studentship</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:fundingRef>RA3/792</gtr:fundingRef><gtr:id>5E2ABAB5-0E5F-4F1A-9A2D-9243F1C52A25</gtr:id><gtr:outcomeId>V4dJEnKFvF30</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MDC Prize studentship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:fundingRef>RA3/839</gtr:fundingRef><gtr:id>B8149224-A13F-42CC-8050-C5F00D33BA72</gtr:id><gtr:outcomeId>BzJrKL795is0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fellowship within Wellcome Trust Ion channels in Disease strategic award</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>Wellcome Trust WT084655MA</gtr:fundingRef><gtr:id>952C6E0B-0EDD-4D93-8089-2AC2F86EE261</gtr:id><gtr:outcomeId>mn2gRBaVTix0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Medical Research Foundation</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E8C8BC7A-BA5C-4FBC-B804-12FB9DC87E98</gtr:id><gtr:outcomeId>G7hf9BCP8pe</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Charitable Trust</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>J P Moulton Charitable Foundation</gtr:fundingOrg><gtr:fundingRef>N/A</gtr:fundingRef><gtr:id>2BA585B9-EFCA-40D0-9CD7-BD727D02F954</gtr:id><gtr:outcomeId>aCKgZfG6W4m</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Defined treatment for patient subsets</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>0B282E0A-37F4-4891-964A-A1DDEFAFCE7D</gtr:id><gtr:impact>Defined that ephedrine or other b2-adrenergic receptor agonists have a dramatic beeneficial effect for patients with DOK7 CMS. Thus this is now standard treatment for this genetic condition. many patients regain ambulation from previous requirement of a wheel chair. We have now defined other patient subsets for which appropriate treatment combinations leads to life-transforming improvement in quality of life. May patients regain ambulation from previously being wheel chair-bound.</gtr:impact><gtr:outcomeId>VUnFmaDdovE</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>We demonstrated this commonly available drug has a remarkable beneficial effect for patients with DOK7 CMS.</gtr:description><gtr:id>84149042-9F55-4AAB-91AE-6937BC5CA38F</gtr:id><gtr:impact>Use of ephedrine in DOK7 CMS patients results in a dramatic improvement in disability scores. For example patients who were in wheel chairs are now often able to run.

Ephedrine and salbutamol (which acts in a similar way) are now therapies of choice for DOK7 CMS</gtr:impact><gtr:outcomeId>G5FqGAjr2XV</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ephedrine</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We have been able to establish salbutamol and ephedrine as treatment of choice for the DOK7 CMS patient subgroups (and other forms of CMS).</gtr:description><gtr:id>2B5ED3D9-28DB-49F0-AAA2-ED62AAA7FEE2</gtr:id><gtr:impact>Salbutamol and ephedrine are already available cheap drugs that have a dramatic beneficial effect of a subgroup of patients that we have defined. Further work is ongoing to establish additional uses for these drugs.</gtr:impact><gtr:outcomeId>PjUikqWtuDR</gtr:outcomeId><gtr:stage>Wide-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>salbutamol</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Transgenic mouse model of disease</gtr:description><gtr:id>95FA9798-7B31-4040-BAC4-1EF5ECAD5E56</gtr:id><gtr:impact>Used to study novel treatments, and optimise combinations of presently used treatments</gtr:impact><gtr:outcomeId>UTYeazEeEgZ</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Model of slow channel syndrome</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mouse model of AChR deficiency syndrome</gtr:description><gtr:id>A55C3C8A-B17C-4538-A762-AFCF5EA782BE</gtr:id><gtr:impact>Cossins et al., 2004.
Used to establish optimum therapeutic strategies for difficult to treat patients.</gtr:impact><gtr:outcomeId>RQh9kmc5Xj8</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Model of AChR deficiency syndrome</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Cell lines from patients with congenital myasthenic syndromes</gtr:description><gtr:id>FA612E1C-5BBD-4003-B2C1-FB4610DB6CFF</gtr:id><gtr:impact>Used in determining underlying disease mechanism and in determining if DNA variants are pathogenic</gtr:impact><gtr:outcomeId>q5Nkpi81Dxt</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>cell line</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>cDNA clones expressing CHRNA, CHRNB, CHRNG, CHRND, CHRNE, RAPSN, AGRN, DOK7,</gtr:description><gtr:id>E5EADB05-8777-4CF7-8E27-6CAD43FCF3C5</gtr:id><gtr:impact>Provided expression constructs to numerous laboratories throughout the world for studies of the neuromuscular junction, both pre and post 2006.</gtr:impact><gtr:outcomeId>ZVfrChBoUDd</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Expression plasmids</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1B202554-62BB-40A0-98B7-686065858719</gtr:id><gtr:title>MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f271914a69e9ac5a7648468bd26c4b07"><gtr:id>f271914a69e9ac5a7648468bd26c4b07</gtr:id><gtr:otherNames>Koneczny I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5464bbb762acc2.29078467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB9A901C-F8D0-4FC5-B175-C3CBAB79DBB2</gtr:id><gtr:title>A treatable muscle disease.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4825c06e28e3e36da21434ee220cd097"><gtr:id>4825c06e28e3e36da21434ee220cd097</gtr:id><gtr:otherNames>Burke G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>FD146BE44A5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3212BFDE-F1AC-4245-9667-F3875165B6DC</gtr:id><gtr:title>Open letter to prime minister David Cameron and health secretary Andrew Lansley.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c947c205bf8cbc9fb19ef6a3f2ff3752"><gtr:id>c947c205bf8cbc9fb19ef6a3f2ff3752</gtr:id><gtr:otherNames>Nicholl DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>K3vLcjzcHqS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74863D60-161A-40C7-8A03-52E3D9CF4448</gtr:id><gtr:title>N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32d68ec8aec7672f0b88995be79ce83f"><gtr:id>32d68ec8aec7672f0b88995be79ce83f</gtr:id><gtr:otherNames>Irani SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>MFiHfnrekJ6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F945F95-F805-40F3-A249-E9C0C10E5E2D</gtr:id><gtr:title>Congenital fibre type disproportion associated with mutations in the tropomyosin 3 (TPM3) gene mimicking congenital myasthenia.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78a0d7fbf3fd3bf8b000674d4ef44ad7"><gtr:id>78a0d7fbf3fd3bf8b000674d4ef44ad7</gtr:id><gtr:otherNames>Munot P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>AxDMeZm9Smp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C57F069-EDA5-4FAF-848A-B22CD0015177</gtr:id><gtr:title>Congenital myasthenic syndromes: an update.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4a622948ab7690627e2ef7352ddf2e"><gtr:id>cb4a622948ab7690627e2ef7352ddf2e</gtr:id><gtr:otherNames>Finlayson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>pm_13880_20_23468559</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9A6D053-9E94-4251-B6D0-433C3D306848</gtr:id><gtr:title>Clinical features in a series of fast channel congenital myasthenia syndrome.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cad527b64016a7b9db06e95b702905ac"><gtr:id>cad527b64016a7b9db06e95b702905ac</gtr:id><gtr:otherNames>Palace J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>ncd5hEHrntc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E8622A5-3282-47AF-9CF3-7DFF9D909B99</gtr:id><gtr:title>Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c1dbe5873652bd62ed0c8c7c781a347"><gtr:id>3c1dbe5873652bd62ed0c8c7c781a347</gtr:id><gtr:otherNames>Robb SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>WDgp9EBruor</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD6AD392-AC80-4074-B4ED-96B63651C182</gtr:id><gtr:title>Muscle dysfunction caused by a KATP channel mutation in neonatal diabetes is neuronal in origin.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e468d947d313423e727868bef5242d"><gtr:id>03e468d947d313423e727868bef5242d</gtr:id><gtr:otherNames>Clark RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>gHi1433siCF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6E204B3-3F9A-451C-99EF-04A36AE57277</gtr:id><gtr:title>Congenital stridor with feeding difficulty as a presenting symptom of Dok7 congenital myasthenic syndrome.</gtr:title><gtr:parentPublicationTitle>International journal of pediatric otorhinolaryngology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/448a153a3accd12a1ab5896d1553e0c7"><gtr:id>448a153a3accd12a1ab5896d1553e0c7</gtr:id><gtr:otherNames>Jephson CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0165-5876</gtr:issn><gtr:outcomeId>oMxoj8cyMuR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04B3E6A8-B6E5-4F20-9ECB-B636E3467413</gtr:id><gtr:title>Myasthenia and related disorders of the neuromuscular junction.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f804d3e647f618a01cc6307129f5106"><gtr:id>6f804d3e647f618a01cc6307129f5106</gtr:id><gtr:otherNames>Spillane J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>mSuMchAzUTR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F139C57B-F82C-475D-B23A-9BEC2DB47706</gtr:id><gtr:title>Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/567a6df44fe9ec1809d4232be794446a"><gtr:id>567a6df44fe9ec1809d4232be794446a</gtr:id><gtr:otherNames>Yang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>CscK7f3FzTs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A513B3DE-29D8-42A6-8CF2-6099436D4086</gtr:id><gtr:title>Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4825c06e28e3e36da21434ee220cd097"><gtr:id>4825c06e28e3e36da21434ee220cd097</gtr:id><gtr:otherNames>Burke G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_13880_20_23219351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>360129E4-4C7B-41B1-8199-1D5967AB68DA</gtr:id><gtr:title>Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71d949c1c28cb9d2a95b1c179c02764b"><gtr:id>71d949c1c28cb9d2a95b1c179c02764b</gtr:id><gtr:otherNames>Senderek J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>eYG7mzHHMbA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65223973-04E0-4908-BB71-DCA76AC3233A</gtr:id><gtr:title>Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9424d7e37ca3a2d7f9ecbaa8e24e2c06"><gtr:id>9424d7e37ca3a2d7f9ecbaa8e24e2c06</gtr:id><gtr:otherNames>Guergueltcheva V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>Tui3oMFwMzm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39D7BB38-665A-4A0E-ADF8-C838834D74A6</gtr:id><gtr:title>The search for new antigenic targets in myasthenia gravis.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51cba051719f81ef2c20624dca20d9fa"><gtr:id>51cba051719f81ef2c20624dca20d9fa</gtr:id><gtr:otherNames>Cossins J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>pm_13880_20_23278587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1502B158-4546-4922-A81D-410E8ECE3771</gtr:id><gtr:title>Identification of DPAGT1 as a new gene in which mutations cause a congenital myasthenic syndrome.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef1daab582c85c7641d8fd3dea00cc9e"><gtr:id>ef1daab582c85c7641d8fd3dea00cc9e</gtr:id><gtr:otherNames>Belaya K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>pm_13880_20_23278575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F37E31E6-4DE2-4D1F-8A7B-80AEADA2E593</gtr:id><gtr:title>LG2 agrin mutation causing severe congenital myasthenic syndrome mimics functional characteristics of non-neural (z-) agrin.</gtr:title><gtr:parentPublicationTitle>Human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58d39624b30e08e260bf425cdd050f0e"><gtr:id>58d39624b30e08e260bf425cdd050f0e</gtr:id><gtr:otherNames>Maselli RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0340-6717</gtr:issn><gtr:outcomeId>pm_13880_20_22205389</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06CD7E7F-33B7-44AA-9B6F-E1AC9A0E5C11</gtr:id><gtr:title>Congenital myasthenic syndromes due to mutations in ALG2 and ALG14.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51cba051719f81ef2c20624dca20d9fa"><gtr:id>51cba051719f81ef2c20624dca20d9fa</gtr:id><gtr:otherNames>Cossins J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_13880_20_23404334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E09FDD9-8EE8-4B42-9061-AE78FBDB14D1</gtr:id><gtr:title>Mutations in GFPT1 that underlie limb-girdle congenital myasthenic syndrome result in reduced cell-surface expression of muscle AChR.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f46ce8597d265963cae03471c26f8e21"><gtr:id>f46ce8597d265963cae03471c26f8e21</gtr:id><gtr:otherNames>Zoltowska K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_13880_20_23569079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>206CC7ED-F73F-424F-809A-A56FED563576</gtr:id><gtr:title>AChR deficiency due to epsilon-subunit mutations: two common mutations in the Netherlands.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eeb3d751d0b3ca25ea1e32f80ae5a41e"><gtr:id>eeb3d751d0b3ca25ea1e32f80ae5a41e</gtr:id><gtr:otherNames>Faber CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>C3716AA52D3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20CA9FD4-8765-44C5-A357-5BE6F77F705A</gtr:id><gtr:title>186th ENMC international workshop: congenital myasthenic syndromes 24-26 June 2011, Naarden, The Netherlands.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92cf2dd7e98f0d1ff4c60ca219551d89"><gtr:id>92cf2dd7e98f0d1ff4c60ca219551d89</gtr:id><gtr:otherNames>Chaouch A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_13880_20_22230109</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23441F74-F8A7-4E91-BF9F-02FCDD4E9947</gtr:id><gtr:title>A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.</gtr:title><gtr:parentPublicationTitle>Journal of biomedicine &amp; biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef44751943f93ad4dcde5a0efad81e55"><gtr:id>ef44751943f93ad4dcde5a0efad81e55</gtr:id><gtr:otherNames>Gattenl?hner S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1110-7243</gtr:issn><gtr:outcomeId>b77vsRa5npA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3970A64B-DD5F-43B2-AF08-1357257CDDA6</gtr:id><gtr:title>The spectrum of mutations that underlie the neuromuscular junction synaptopathy in DOK7 congenital myasthenic syndrome.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51cba051719f81ef2c20624dca20d9fa"><gtr:id>51cba051719f81ef2c20624dca20d9fa</gtr:id><gtr:otherNames>Cossins J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_13880_20_22661499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>698DAB21-C831-43E3-B051-4633A471606B</gtr:id><gtr:title>Germline mutation in DOK7 associated with fetal akinesia deformation sequence.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/285a802c943a5110f6b6faba4bfcd846"><gtr:id>285a802c943a5110f6b6faba4bfcd846</gtr:id><gtr:otherNames>Vogt J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>F1CAA0A973C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>129AE64C-D0A1-44C4-8A13-6BAB811186A4</gtr:id><gtr:title>Congenital myasthenic syndrome due to homozygous CHRNE mutations: report of patients in Arabia.</gtr:title><gtr:parentPublicationTitle>Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3cd280e600e16470011d1c47d31f5dc1"><gtr:id>3cd280e600e16470011d1c47d31f5dc1</gtr:id><gtr:otherNames>Salih MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1070-8022</gtr:issn><gtr:outcomeId>sWdS3caDCfE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFC5C32C-9757-4856-9118-068574E8D5A8</gtr:id><gtr:title>DOK7 congenital myasthenic syndrome in childhood: early diagnostic clues in 23 children.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7d7dab9bcd362c812ec7147699561da"><gtr:id>d7d7dab9bcd362c812ec7147699561da</gtr:id><gtr:otherNames>Klein A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_13880_20_23831158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F3C09D6-8BAA-46BE-9E29-959706DB5C13</gtr:id><gtr:title>A novel congenital myasthenic syndrome due to decreased acetylcholine receptor ion-channel conductance.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f022b8687d82dc8df9d836a488d074d"><gtr:id>8f022b8687d82dc8df9d836a488d074d</gtr:id><gtr:otherNames>Webster R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_13880_20_22382357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5751A2E-F52F-4D88-A2B8-24BF17E93137</gtr:id><gtr:title>Clinical features in a large Iranian family with a limb-girdle congenital myasthenic syndrome due to a mutation in DPAGT1.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1da1c479595c8ce8d6530aff38bd4bea"><gtr:id>1da1c479595c8ce8d6530aff38bd4bea</gtr:id><gtr:otherNames>Basiri K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_13880_20_23591138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF6FF148-98F2-4DE0-B9E6-674BD090AC82</gtr:id><gtr:title>A mouse model of the slow channel myasthenic syndrome: Neuromuscular physiology and effects of ephedrine treatment.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7526f3636d632aaa7edc6a8cdb921b5b"><gtr:id>7526f3636d632aaa7edc6a8cdb921b5b</gtr:id><gtr:otherNames>Webster RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>pm_13880_20_23797154</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6631D6D4-366E-4749-9EB6-D619B553C6F6</gtr:id><gtr:title>Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4a622948ab7690627e2ef7352ddf2e"><gtr:id>cb4a622948ab7690627e2ef7352ddf2e</gtr:id><gtr:otherNames>Finlayson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_13880_20_23447650</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2473A85B-F7D0-49D0-9B47-75D74998D2B0</gtr:id><gtr:title>Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef1daab582c85c7641d8fd3dea00cc9e"><gtr:id>ef1daab582c85c7641d8fd3dea00cc9e</gtr:id><gtr:otherNames>Belaya K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>pm_13880_20_22742743</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D79F8DB3-5A49-4556-9DCD-3DFA7988FFC7</gtr:id><gtr:title>Antibodies identified by cell-based assays in myasthenia gravis and associated diseases.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/574f973bede4fd9f446edfa9f6f58020"><gtr:id>574f973bede4fd9f446edfa9f6f58020</gtr:id><gtr:otherNames>Vincent A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>pm_13880_20_23252902</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D1FD21C-8F73-42C3-BAD8-944D0F92FD11</gtr:id><gtr:title>Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e276ccacd56645b7df892df1f87c8ef"><gtr:id>8e276ccacd56645b7df892df1f87c8ef</gtr:id><gtr:otherNames>Lashley D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>XB8NjYmnptT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8FF2766-485E-4CF0-9C93-E0FEB1D1A8F6</gtr:id><gtr:title>Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4a622948ab7690627e2ef7352ddf2e"><gtr:id>cb4a622948ab7690627e2ef7352ddf2e</gtr:id><gtr:otherNames>Finlayson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_13880_20_23281026</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701521</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>